A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin a in traumatic brain injury

Neurosurgery

Volumn 68, Issue 5, 2011, Pages 1172-1185

  Lulic, Dzenan ^a   Burns, Jack ^a   Bae, Eunkyung Cate ^a   Van Loveren, Harry ^a   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Central nervous system; Cyclosporin A; Immunosuppressant; Neuroprotection; Neurotrauma

Indexed keywords

CALCIUM ION; CYCLOPHILIN A; CYCLOSPORIN A; NITRIC OXIDE SYNTHASE; PLACEBO; REACTIVE OXYGEN METABOLITE; TACROLIMUS;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN MITOCHONDRION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LIPID PEROXIDATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PILOT STUDY; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

ANIMALS; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 79955028262     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31820c6cdc     Document Type: Article

References (109)

1. Sosin DM, Sniezek JE, Waxweiler RJ. Trends in death associated with traumatic brain injury, 1979 through 1992. Success and failure. JAMA. 1995;273(22): 1778-1780.
2. Waxweiler RJ, Thurman D, Sniezek J, Sosin D, O'Neil J. Monitoringthe impact of traumatic brain injury: a review and update. J Neurotrauma. 1995;12(4): 509-516.
3. Thurman D. Epidemiology and economics of head trauma. In: Miller LP, Hayes RL, eds. Head Trauma: Basic, Preclinical, and Clinical Directions. New York: Wiley-Liss; 2001:327-347.
4. Guidelines for the management ofsevere traumatic brain injury. JNeurotrauma. 2007;24(Suppl 1):S1-S106.
5. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728-741. (Pubitemid 351957931)
6. Paci GM, Sise MJ, Sise CB, et al. Preemptive craniectomy with craniotomy: what role in the management of severe traumatic brain injury? J Trauma. 2009;67(3):531-536.
7. Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology ofnature. Curr Opin Crit Care. 2007;13(2):134-142. (Pubitemid 46328326)
8. Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeutics. 2009;6(1):28-42.
9. Wang KK, Larner SF, Robinson G, Hayes RL. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol. 2006;19(6):514-519. (Pubitemid 44760432)
10. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science. 1989;244(4906): 798-800. (Pubitemid 19163864)
11. Okonkwo DO, Povlishock JT. Immunosupresants in traumatic brain injury. In: Borlongan CV, Isacson O, Sanberg PR, eds. Immunosuppresants Analogs in Neuroprotection. Totowa, NJ: Humana Press; 2003.
12. Sun DA, Deshpande LS, Sombati S, et al. Traumatic brain injury causes a long-lasting calcium (Ca2+)-plateau of elevated intracellular Ca levels and altered Ca2+ homeostatic mechanisms in hippocampal neurons surviving brain injury. Eur J Neurosci. 2008;27(7):1659-1672. (Pubitemid 351473592)
13. Buki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neuro-trauma. 1999;16(6):511-521. (Pubitemid 29297905)
14. Povlishock JT, Marmarou A, McIntosh T, Trojanowski JQ, Moroi J. Impact acceleration injury in the rat: evidence for focal axolemmal change and related neurofilament sidearm alteration. J Neuropathol Exp Neurol. 1997;56(4):347-359. (Pubitemid 27465017)
15. Pettus EH, Povlishock JT. Characterization of a distinct set of intra-axonal ultrastructural changes associated with traumatically induced alteration in ax-olemmal permeability. Brain Res. 1996;722(1-2):1-11. (Pubitemid 26199353)
16. Lifshitz J, Sullivan PG, Hovda DA, Wieloch T, McIntosh TK. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion. 2004; 4(5-6):705-713. (Pubitemid 39646816)
17. Castilho RF, Kowaltowski AJ, Vercesi AE. The irreversibility of inner mito-chondrial membrane permeabilization by Ca2+ plus prooxidants is determined by the extent of membrane protein thiol cross-linking. J Bioenerg Biomembr. 1996;28(6):523-529.
18. Crompton M, Virji S, Doyle V, Johnson N, Ward JM. The mitochondrial permeability transition pore. Biochem Soc Symp. 1999;66:167-179. (Pubitemid 129639031)
19. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281(5381): 1309-1312. (Pubitemid 28406816)
20. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie. 2002;84(2-3):153-166.
21. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? JNeurosci Res. 2005;79(1-2):231-239. (Pubitemid 40116440)
22. Hayashi T, Kaneko Y, Yu S, et al. Quantitative analyses of matrix metal-loproteinase activity after traumatic brain injury in adult rats. Brain Res. 2009;1280:172-177.
23. Vilalta A, Sahuquillo J, Rosell A, Poca MA, Riveiro M, Montaner J. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med. 2008;34(8):1384-1392.
24. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci. 1996;16(8):2479-2487. (Pubitemid 26122672)
25. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to per-oxynitrite-mediated cellular injury. Proc Natl Acad Sci USA. 1996;93(13): 6770-6774.
26. Fee D, Crumbaugh A, Jacques T, et al. Activated/effector CD4+ T cells exac-erbate acute damage in the central nervous system following traumatic injury. J Neuroimmunol. 2003;136(1-2):54-66. (Pubitemid 36298844)
27. Hailer NP. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol. 2008;84(3):211-233.
28. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects ofcyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6(4):468-475.
29. Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM. Expression ofinducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology. 1994;33(11):1425-1430. (Pubitemid 24353737)
30. Palladini G, Caronti B, Pozzessere G, et al. Treatment with cyclosporine A promotes axonal regeneration in rats submitted to transverse section ofthe spinal cord-II-Recovery of function. JHirnforsch. 1996;37(1):145-153. (Pubitemid 126441102)
31. Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action ofimmunosuppressants-facts and hypotheses.J Cell Mol Med. 2004;8(1):45-58. (Pubitemid 44145522)
32. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calci-neurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807-815. (Pubitemid 121001714)
33. Cardenas ME, Muir RS, Breuder T, Heitman J. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calci-neurin A. EMBOJ. 1995;14(12):2772-2783.
34. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity inT lymphocytes is inhibitedby FK506 and cyclosporin A. Proc Natl Acad Sci USA. 1992;89(9):3686-3690.
35. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD. Neural actionsofimmunophilinligands. Trends Pharmacol Sci. 1998;19(1):21-26.
36. Goldner FM, Patrick JW. Neuronal localization ofthe cyclophilin A protein in the adult rat brain. J Comp Neurol. 1996;372(2):283-293. (Pubitemid 26275214)
37. Borlongan CV, Fujisaki T, Watanabe S. Chronic cyclosporine-A injection in rats with damaged blood-brain barrier does not impair retention of passive avoidance. Neurosci Res. 1998;32(3):195-200. (Pubitemid 28559209)
38. Leventhal L, Sortwell CE, Hanbury R, Collier TJ, Kordower JH, Palfi S. Cy-closporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity.J Comp Neurol. 2000;425(4):471-478.
39. Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in ex-perimental brain tumors. J Cereb Blood Flow Metab. 1994;14(5):862-870. (Pubitemid 24266539)
40. Nomura T, Inamura T, Black KL. Intracarotid infusion ofbradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 1994;659(1-2):62-66. (Pubitemid 24292845)
41. Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation ofBBB perme-ability using the bradykinin agonist, RMP-7. Exp Neurol. 1996;142(1):14-28. (Pubitemid 26381377)
42. Okonkwo DO, Melon DE, Pellicane AJ, et al. Dose-response ofcyclosporin A in attenuating traumatic axonal injury in rat. Neuroreport. 2003;14(3):463-466. (Pubitemid 36337951)
43. Diaz-Ruiz A, Rios C, Duarte I, et al. Cyclosporin-A inhibits lipid peroxidation after spinal cord injury in rats. Neurosci Lett. 1999;266(1):61-64. (Pubitemid 29219756)
44. Vercesi AE, Kowaltowski AJ, Grijalba MT, Meinicke AR, Castilho RF. The role of reactive oxygen species in mitochondrial permeability transition. Biosci Rep. 1997;17(1):43-52. (Pubitemid 27267591)
45. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol. 2007;9(5):550-555. (Pubitemid 46696536)
46. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide trans-locase confirms their role in the mitochondrial permeability transition. Biochem J. 1998;336(Pt 2):287-290. (Pubitemid 28564382)
47. Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ. Inhibition of the mito-chondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol Pharmacol. 2002;62(1):22-29. (Pubitemid 34680512)
48. Schinzel AC, Takeuchi O, Huang Z, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA. 2005;102(34):12005-12010. (Pubitemid 41291119)
49. Malouitre S, Dube H, Selwood D, Crompton M. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J. 2010;425(1): 137-148.
50. Wang X, Carlsson Y, Basso E, et al. Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J Neurosci. 2009;29(8): 2588-2596.
51. Wang X, Han W, Du X, et al. Neuroprotective effect ofbax-inhibiting peptide on neonatal brain injury. Stroke. 2010;41(9):2050-2055.
52. Nicolli A, Basso E, Petronilli V, Wenger RM, Bernardi P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel. J Biol Chem. 1996;271(4):2185-2192. (Pubitemid 26047809)
53. He L, Lemasters JJ. Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function? FEBS Lett. 2002;512(1-3):1-7. (Pubitemid 34164440)
54. Santos JB, Schauwecker PE. Protection provided by cyclosporin A against ex-citotoxic neuronal death is genotype dependent. Epilepsia. 2003;44(8):995-1002. (Pubitemid 36959304)
55. Cousin MA, Robinson PJ. The dephosphins: dephosphorylation by calcineurin triggers synaptic vesicle endocytosis. Trends Neurosci. 2001;24(11):659-665. (Pubitemid 33152773)
56. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation ofnitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA. 1993;90(21):9808-9812. (Pubitemid 23328199)
57. Shou Y, Li L, Prabhakaran K, Borowitz JL, Isom GE. Calcineurin-mediated Bad translocation regulates cyanide-induced neuronal apoptosis. Biochem J. 2004;379(Pt 3):805-813. (Pubitemid 38703665)
58. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through cal-cineurin dephosphorylation ofBAD. Science. 1999;284(5412):339-343. (Pubitemid 129523456)
59. Costantini LC, Chaturvedi P, Armistead DM, McCaffrey PG, Deacon TW, Isacson O. A novel immunophilin ligand: distinct branching effects on dopa-minergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol Dis. 1998;5(2):97-106. (Pubitemid 28430720)
60. Costantini LC, Isacson O. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. Exp Neurol. 2000;164(1):60-70. (Pubitemid 30490723)
61. Gabryel B, Bernacki J. Effect ofFK506 and cyclosporine A on the expression of BDNF, tyrosine kinase B and p75 neurotrophin receptors in astrocytes exposed to simulated ischemia in vitro. Cell Biol Int. 2009;33(7):739-748.
62. Okonkwo DO, Buki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport. 1999;10(2):353-358. (Pubitemid 29104812)
63. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999;19(4):443-451. (Pubitemid 30161232)
64. Scheff SW, Sullivan PG. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma. 1999;16(9):783-792.
65. Gogarten W, Van Aken H, Moskopp D, et al. A case ofsevere cerebral trauma in a patient under chronic treatment with cyclosporine A. J Neurosurg Anesthesiol. 1998;10(2):101-105. (Pubitemid 28177882)
66. Suehiro E, Povlishock JT. Exacerbation oftraumatically induced axonal injury by rapid posthypothermic rewarming and attenuation of axonal change by cyclo-sporin A. J Neurosurg. 2001;94(3):493-498. (Pubitemid 32786031)
67. Van Den Heuvel C, Donkin JJ, Finnie JW, et al. Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J Neurotrauma. 2004;21(11):1562-1572. (Pubitemid 39525166)
68. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399(6738 Suppl):A23-A31.
69. Gabbita SP, Scheff SW, Menard RM, Roberts K, Fugaccia I, Zemlan FP. Cleaved-tau: a biomarker of neuronal damage after traumatic brain injury. J Neurotrauma. 2005;22(1):83-94.
70. Zemlan FP, Mulchahey JJ, Gudelsky GA. Quantification and localization ofkainic acid-induced neurotoxicity employing a new biomarker of cell death: cleaved microtubule-associated protein-tau (C-tau). Neuroscience. 2003;121(2):399-409. (Pubitemid 37176927)
71. Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mi-tochondrial dysfunction following traumatic brain injury. Exp Neurol. 1999;160(1):226-234.
72. Signoretti S, Marmarou A, Tavazzi B, et al. The protective effect ofcyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury. J Neurotrauma. 2004;21(9):1154- 1167. (Pubitemid 39280843)
73. Albensi BC, Sullivan PG, Thompson MB, Scheff SW, Mattson MP. Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol. 2000;162(2):385-389. (Pubitemid 30217732)
74. Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma. 2002;19(7):829-841. (Pubitemid 34815501)
75. Riess P, Bareyre FM, Saatman KE, et al. Effects ofchronic, post-injury Cyclo-sporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury. Restor Neurol Neurosci. 2001;18(1):1-8. (Pubitemid 32881789)
76. Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol. 2008;3(3):166-173.
77. Sullivan PG, Rabchevsky AG, Hicks RR, Gibson TR, Fletcher-Turner A, Scheff SW. Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats. Neuroscience. 2000;101(2):289-295.
78. Sullivan PG, Thompson M, Scheff SW. Continuous infusion ofcyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol. 2000;161(2):631-637. (Pubitemid 30137020)
79. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. JNeurol. 1999;246(5):339-346. (Pubitemid 29261421)
80. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7(11):937-942. (Pubitemid 33085781)
81. Jayakumar AR, Rao KV, Panickar KS, Moriyama M, Reddy PV, Norenberg MD. Trauma-induced cell swelling in cultured astrocytes. J Neuropathol Exp Neurol. 2008;67(5):417-427. (Pubitemid 351653534)
82. Redell JB, Zhao J, Dash PK. Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007;85(9):1980-1988. (Pubitemid 47051486)
83. Fukui S, Signoretti S, Dunbar JG, Marmarou A. The effect ofcyclosporin A on brain edema formation following experimental cortical contusion. Acta Neurochir Suppl. 2003;86:301-303.
84. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004;4(2):97-107. (Pubitemid 38584972)
85. Setkowicz Z, Guzik R. Injections ofvehicle, but not cyclosporin A or tacrolimus (FK506), afford neuroprotection following injury in the developing rat brain. Acta Neurobiol Exp (Wars). 2007;67(4):399-409.
86. Borlongan CV. Motor activity-mediated partial recovery in ischemic rats. Neuroreport. 2000;11(18):4063-4067. (Pubitemid 32038804)
87. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spon-taneous recovery. Ann Neurol. 2008;63(3):272-287. (Pubitemid 351499857)
88. Liu Z, Zhang RL, Li Y, Cui Y, Chopp M. Remodeling of the corticospinal innervation and spontaneous behavioral recovery after ischemic stroke in adult mice. Stroke. 2009;40(7):2546-2551.
89. Anand P, Birch R. Restoration ofsensory function and lack oflong-term chronic pain syndromes after brachial plexus injury in human neonates. Brain. 2002;125(Pt 1):113-122. (Pubitemid 34084041)
90. Ashwal S, Tone B, Tian HR, Chong S, Obenaus A. Serial magnetic resonance imaging in a rat pup filament stroke model. Exp Neurol. 2006;202(2):294-301. (Pubitemid 44692674)
91. Burgess JW, Villablanca JR. Recovery of function after neonatal or adult hemispherectomy in cats. II. Limb bias and development, paw usage, locomotion and rehabilitative effects of exercise. Behav Brain Res. 1986;20(1):1-17.
92. Derugin N, Dingman A, Wendland MF, Fox C, Bollen A, Vexler ZS. Magnetic resonance imaging as a surrogate measure for histological sub-chronic endpoint in a neonatal rat stroke model. Brain Res. 2005;1066(1-2):49-56. (Pubitemid 41790728)
93. Villablanca JR, Burgess JW, Olmstead CE. Recovery offunction after neonatal or adult hemispherectomy in cats: I. Time course, movement, posture and senso-rimotor tests. Behav Brain Res. 1986;19(3):205-226. (Pubitemid 16137881)
94. McEwen ML, Sullivan PG, Springer JE. Pretreatment with the cyclosporin derivative, NIM811, improves the function ofsynaptic mitochondria following spinal cord contusion in rats. JNeurotrauma. 2007;24(4):613-624 (Pubitemid 46996022)
95. Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neu-roprotective effects ofcyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab. 2009;29(1):87-97.
96. Mbye LH, Singh IN, Sullivan PG, Springer JE, Hall ED. Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. Exp Neurol. 2008;209(1):243-253.
97. Yu S, Kaneko Y, Bae E, et al. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain Res. 2009;1287:157-163.
98. Kasturi BS, Stein DG. Progesterone decreases cortical and sub-cortical edema in young and aged ovariectomized rats with brain injury. Restor Neurol Neurosci. 2009;27(4):265-275.
99. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog Brain Res. 2009;175:219-237.
100. Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. Cyclosporin A dis-position following acute traumatic brain injury.J Neurotrauma. 2006;23(1):109-116. (Pubitemid 43191091)
101. Boddie DE, Currie DG, Eremin O, Heys SD. Immune suppression and isolated severe head injury: a significant clinical problem. Br J Neurosurg. 2003;17(5): 405-417. (Pubitemid 37421565)
102. Mazzeo AT, Kunene NK, Gilman CB, Hamm RJ, Hafez N, Bullock MR Severe human traumatic brain injury, but not cyclosporin a treatment, depresses acti-vated T lymphocytes early after injury. J Neurotrauma. 2006;23(6):962-975. (Pubitemid 43962855)
103. Mazzeo AT, Alves OL, Gilman CB, et al. Brain metabolic and hemodynamic effects ofcyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien). 2008;150(10):1019-1031; discussion 1031.
104. Marcoux J, McArthur DA, Miller C, et al. Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury. Crit Care Med. 2008;36(10): 2871-2877.
105. Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. 2005;25(6):763-774. (Pubitemid 40705611)
106. Vespa PM, McArthur D, O'Phelan K, et al. Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite alackofincreasedlactate: amicrodialysis study.J Cereb Blood Flow Metab. 2003;23(7):865-877. (Pubitemid 36818694)
107. Richards DA, Tolias CM, Sgouros S, Bowery NG. Extracellular glutamine to glutamate ratio may predict outcome in the injured brain: a clinical microdialysis study in children. Pharmacol Res. 2003;48(1):101-109. (Pubitemid 36593365)
108. Hatton J, Rosbolt B, Empey P, Kryscio R, Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg. 2008;109(4): 699-707.
109. Mazzeo AT, Brophy GM, Gilman CB, et al. Safety and tolerability ofcyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma. 2009;26(12):2195-2206.